biotech semaglutide Semaglutide | C187H291N45O59 | CID

Description

Contamination is another risk

Its dual-action GIP/GLP-1 mechanism produced an average 22% weight reduction in clinical trials, results previously only achievable with bariatric surgery

A 2025 preclinical study reported modulation of senescence-related pathways consistent with improved cellular function, though translation to human aging remains uncertain [17]

The simplest way to keep them straight is by counting receptors: semaglutide acts on one (GLP-1), tirzepatide on two (GLP-1 and GIP), and retatrutide on three (GLP-1, GIP, and glucagon)

Why I Decided to Try a GLP-1 When I first started hearing about GLP-1 medications like Ozempic around 2022, I was scared off by the stories of side effects and potential issues like stomach paralysis, pancreatitis, and cancer